Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Infinity Pharmaceuticals Inc (NASDAQ:INFI)

2.15
Delayed Data
As of Apr 28
 +0.05 / +2.38%
Today’s Change
0.84
Today|||52-Week Range
6.20
+59.26%
Year-to-Date
Alkermes (ALKS) Q1 Loss Wider than Expected, Sales Miss
Apr 28 / Zacks.com - Paid Partner Content
Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III
Apr 19 / Zacks.com - Paid Partner Content
Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View
Apr 27 / Zacks.com - Paid Partner Content
Why Is Infinity (INFI) Down 37.4% Since the Last Earnings Report?
Apr 19 / Zacks.com - Paid Partner Content
Alexion (ALXN) Tops Q1 Earnings, Revenues; Ups '17 View
Apr 27 / Zacks.com - Paid Partner Content
AMAG Files for FDA Approval of Subcutaneous Form of Makena
Apr 18 / Zacks.com - Paid Partner Content
Celgene (CELG) Tops on Q1 Earnings, Sales Miss, Raises View
Apr 27 / Zacks.com - Paid Partner Content
Infinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19%
Apr 18 / Zacks.com - Paid Partner Content
AbbVie (ABBV) Presents Positive Data on HCV Combination Drug
Apr 21 / Zacks.com - Paid Partner Content
Bio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher
Apr 17 / Zacks.com - Paid Partner Content
Nivalis' (NVLS) Shares Down After Merger Deal with Alpine
Apr 20 / Zacks.com - Paid Partner Content